ClassID:

96981

C07K14/575 - CPC Classification

Classification description:

Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans Hormones

Sub-classes:
Recent Application in this class:
#1
20260152539
2026-06-04

MODIFIED MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS AND USES THEREOF FOR THE TREATMENT OF DISEASES

#2
20260152538
2026-06-04

AMYLIN ANALOGUES

#3
20260139023
2026-05-21

NOVEL IRISIN PEPTIDES AND METHODS OF USE THEREOF

#4
20260132182
2026-05-14

CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS

#5
20260132181
2026-05-14

MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS FOR OVARIAN AND UTERINE ONCOPROTECTION, AND OVARIAN RESERVE AND UTERINE PRESERVATION

#6
20260125442
2026-05-07

PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST

#7
20260125441
2026-05-07

PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST

#8
20260125440
2026-05-07

INCRETIN ANALOGS AND USES THEREOF

#9
20260124255
2026-05-07

Salmonella vectored therapies for treatment of cancer

#10
20260115256
2026-04-30

HUMAN AMYLIN ANALOG, AND DERIVATIVE THEREOF AND USE THEREOF

#11
20260103499
2026-04-16

BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS

#12
20260098071
2026-04-09

GLP-1 Analog and Use Thereof in Treatment of GLP-1 Related Diseases

#13
20260092120
2026-04-02

COMPOSITIONS AND METHODS

#14
20260091086
2026-04-02

POLYPEPTIDE COMBINATIONS AND USES THEREOF

#15
20260035428
2026-02-05

A GIP/GLP1 FOR USE IN THERAPY

#16
20260022151
2026-01-22

PHASE TRANSITION ADJUSTING ELEMENT AND USE THEREOF

#17
20260015399
2026-01-15

SOLUBLE NPY2 RECEPTOR AGONISTS

#18
20260008829
2026-01-08

TARGETING ANABOLIC DRUGS FOR ACCELERATED FRACTURE REPAIR

#19
20260001928
2026-01-01

CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY

#20
20250382344
2025-12-18

Soluble GLP1/GIP/NPY2 Receptor Triple Agonists

#21
20250376497
2025-12-11

ARTIFICIAL PROTEIN AND USES THEREOF

#22
20250361281
2025-11-27

AMYLIN RECEPTOR (hAMY3R) AGONISTS WITH IMPROVED CHEMICAL STABILITY

#23
20250361280
2025-11-27

CONJUGATED HEPCIDIN MIMETICS

#24
20250340608
2025-11-06

HEPCIDIN ANALOGUES AND USES THEREOF

#25
20250326814
2025-10-23

MODIFIED OXYNTOMODULIN AND METHODS OF USE THEREOF

#26
20250304642
2025-10-02

PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST

#27
20250296973
2025-09-25

TREATMENT METHOD USING MAZDUTIDE

#28
20250296972
2025-09-25

KLOTHO DERIVATIVES WITH MODIFIED STRUCTURE

#29
20250296971
2025-09-25

GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS

#30
20250289860
2025-09-18

POLYPEPTIDES AND USES THEREOF

#31
20250277012
2025-09-04

CONJUGATED HEPCIDIN MIMETICS

#32
20250270269
2025-08-28

DUAL FUNCTION PROTEINS COMPRISING FGF21 MUTANT PROTEIN AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

#33
20250235508
2025-07-24

MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF

#34
20250228979
2025-07-17

BIOLOGICAL DEVICES AND COMPOSITIONS FOR INCREASING HAIR GROWTH AND METHODS OF USE THEREOF

#35
20250179217
2025-06-05

Enhanced Immunogenicity For GPI-anchored Antigens

#36
20250170216
2025-05-29

CONJUGATED HEPCIDIN MIMETICS

#37
20250161415
2025-05-22

METHOD OF TREATING DISEASE OR DISORDER USING COMPOSITIONS COMPRISING PHARMACEUTICALLY ACCEPTABLE SALTS OF AMYLIN ANALOGS

#38
20250154219
2025-05-15

PEPTIDE ANALOGS

#39
20250145681
2025-05-08

FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES

#40
20250144180
2025-05-08

COMPOSITIONS COMPRISING THERAPEUTIC PROTEINS OR PEPTIDES, AND USES THEREOF

#41
20250129134
2025-04-24

HAM15 52 ANALOGUES WITH IMPROVED AMYLIN RECEPTOR (HAMY3R) POTENCY

#42
20250122257
2025-04-17

USE OF KININ OR DERIVATIVE THEREOF IN TREATING VCI, PSCI, OR CSVD

#43
20250099546
2025-03-27

SATIATION PEPTIDE ADMINISTRATION

#44
20250090622
2025-03-20

ANGIOTENSIN COMPOSITIONS AND METHODS RELATED THERETO

#45
20250084142
2025-03-13

LONG ACTING PEPTIDE TYROSINE TYROSINE (PYY) ANALOGS AND METHODS OF USE

#46
20250064895
2025-02-27

AMYLIN ANALOGUES

#47
20250059250
2025-02-20

PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST

#48
20250049891
2025-02-13

NOVEL PEPTIDE DERIVATIVE DERIVED FROM ADIPONECTIN AND USE THEREOF

#49
20250042958
2025-02-06

COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROTEOPATHIES

#50
20250026803
2025-01-23

IMMUNOGLOBULINS AND USES THEREOF

#51
20250026802
2025-01-23

CHIMERIC ADIPONECTIN POLYPEPTIDES, EXTRACELLULAR VESICLE COMPRISING THE SAME, AND USES THEREOF

#52
20250025533
2025-01-23

LONG-ACTING AMYLIN RECEPTOR AGONISTS AND USES THEREOF

#53
20250018028
2025-01-16

SELF-REPLICATING RNA AND USES THEREOF

#54
20250009876
2025-01-09

HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF

#55
20240417438
2024-12-19

HUMAN AMYLIN ANALOG POLYPEPTIDES AND METHODS OF USE

#56
20240400634
2024-12-05

PEPTIDE IMMUNOGENS TARGETING ISLET AMYLOID POLYPEPTIDE (IAPP) AND FORMULATIONS THEREOF FOR PREVENTION AND TREATMENT OF DISORDERS RELATED TO AGGREGATED IAPP

#57
20240398884
2024-12-05

PLANT MESSENGER PACKS ENCAPSULATING POLYPEPTIDES AND USES THEREOF

#58
20240383959
2024-11-21

CELL-FREE METHODS AND COMPOSITIONS COMPRISING TAGLESS THERAPEUTIC HORMONES

#59
20240383958
2024-11-21

APELIN RECEPTOR AGONISTS AND USES THEREOF

#60
20240358793
2024-10-31

METHOD FOR PROMOTING BONE GROWTH USING ACTIVIN-ACTRIIA ANTAGONISTS

#61
20240352085
2024-10-24

GENETICALLY MODIFIED PROBIOTICS FOR ORAL DELIVERY OF RENIN-ANGIOTENSIN RELATED THERAPEUTIC PROTEINS AND PEPTIDES

#62
20240336668
2024-10-10

IONIC LIQUID COMPOSITIONS

#63
20240325323
2024-10-03

IONIC LIQUID COMPOSITIONS

#64
20240307499
2024-09-19

Compositions comprising pharmaceutically acceptable salts of glucagon-like peptide-1 analogs and uses thereof

#65
20240294608
2024-09-05

ELP FUSION PROTEINS FOR CONTROLLED AND SUSTAINED RELEASE

#66
20240293552
2024-09-05

Compositions comprising pharmaceutically acceptable salts of amylin analogs and uses thereof

#67
20240279299
2024-08-22

CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS

#68
20240277814
2024-08-22

Compositions comprising pharmaceutically acceptable salts of glucagon-like peptide-1 analogs and uses thereof

#69
20240262881
2024-08-08

FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES

#70
20240226225
2024-07-11

CONJUGATED HEPCIDIN MIMETICS

#71
20240218040
2024-07-04

Fusion proteins for the treatment of cardiometabolic diseases

#72
20240218038
2024-07-04

COMPOSITIONS AND METHODS FOR PREVENTING OR DELAYING PUBERTY IN PREPUBESCENT NON-HUMAN ANIMALS AND HUMANS

#73
20240209054
2024-06-27

GIP AGONIST COMPOUNDS AND METHODS

#74
20240209053
2024-06-27

CONJUGATED HEPCIDIN MIMETICS

#75
20240209029
2024-06-27

ADIPONECTIN GLYCOPEPTIDES AND COMPOSITIONS AND METHODS OF USE THEREOF

#76
20240199716
2024-06-20

MODIFIED B-TYPE NATRIURETIC PEPTIDE

#77
20240197860
2024-06-20

Self-replicating RNA and uses thereof

#78
20240190938
2024-06-13

GIP DERIVATIVES AND USES THEREOF

#79
20240189423
2024-06-13

BISPECIFIC BINDING AGENT-LIGAND FUSIONS FOR THE DEGRADATION OF TARGET PROTEINS

#80
20240174726
2024-05-30

Hepcidin analogues and uses thereof

#81
20240173383
2024-05-30

COMPOSITIONS COMPRISING RELAXIN AND METHODS OF USE THEREOF

#82
20240166708
2024-05-23

Long acting peptide tyrosine tyrosine (PYY) analogs and methods of use

#83
20240150426
2024-05-09

BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS

#84
20240101634
2024-03-28

HAManalogues with improved amylin receptor (hAMY3R) potency

#85
20240067693
2024-02-29

POLYPEPTIDES AND USES THEREOF

#86
20240067692
2024-02-29

MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS FOR OVARIAN AND UTERINE ONCOPROTECTION, AND OVARIAN RESERVE AND UTERINE PRESERVATION

#87
20240066131
2024-02-29

CONJUGATED HEPCIDIN MIMETICS

#88
20240059753
2024-02-22

COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE

#89
20240034765
2024-02-01

SCG2 NEUROPEPTIDES AND USES THEREOF

#90
20240018274
2024-01-18

Enhanced immunogenicity for GPI-anchored antigens

#91
20240018208
2024-01-18

CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS

#92
20240002433
2024-01-04

AMINO DIACIDS CONTAINING PEPTIDE MODIFIERS

#93
20230399388
2023-12-14

METHODS FOR TREATING INFLAMMATION USING ANTIBODIES TO KALLIDIN AND DES-ARG10-KALLIDIN

#94
20230381331
2023-11-30

GIP DERIVATIVE, LONG-ACTING CONJUGATE THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

#95
20230374095
2023-11-23

INTER-APPLICATION WORKFLOW PERFORMANCE ANALYTICS

#96
20230365644
2023-11-16

ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS

#97
20230365643
2023-11-16

PEPTIDE, AND COSMETIC COMPOSITION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

#98
20230332135
2023-10-19

MIRAC PROTEINS

#99
20230331803
2023-10-19

Co-agonists of the GLP-1 and amylin receptors

#100
20230331769
2023-10-19

METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN

#101
20230322886
2023-10-12

RECOMBINANT PROTEIN COMPRISING MULTIPLE MULTI-PEPTIDE SETS, PHARMACEUTICAL COMPOSITION COMPRISING THE RECOMBINANT PROTEIN, AND METHOD FOR PREPARING THE RECOMBINANT PROTEIN

#102
20230322872
2023-10-12

RECOMBINANT PROTEIN COMPRISING MULTIPLE MULTI-PEPTIDE SETS, PHARMACEUTICAL COMPOSITION COMPRISING THE RECOMBINANT PROTEIN, AND METHOD FOR PREPARING THE RECOMBINANT PROTEIN

#103
20230310623
2023-10-05

COMPOSITIONS AND METHODS FOR TARGETING TUMOR ASSOCIATED TRANSCRIPTION FACTORS

#104
20230295259
2023-09-21

Conjugated Hepcidin Mimetics

#105
20230279068
2023-09-07

Targeting anabolic drugs for accelerated fracture repair

#106
20230250132
2023-08-10

METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN

#107
20230242577
2023-08-03

METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN

#108
20230242576
2023-08-03

METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN

#109
20230242575
2023-08-03

METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN

#110
20230242574
2023-08-03

METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN

#111
20230242573
2023-08-03

METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN

#112
20230174607
2023-06-08

Novel Adrenomedullin Analog, Method for Producing the Same, and Pharmaceutical Use Thereof

#113
20230174591
2023-06-08

Use of Human Resistin as a Trimerization Partner for Expression of Trimeric Proteins

#114
20230173076
2023-06-08

METABOLICALLY STABLE PEPTIDE ANALOGS

#115
20230159602
2023-05-25

ENGINEERED OPTIMIZED CYTOKINE COMPOSITIONS

#116
20230158117
2023-05-25

COMPOSITION FOR PREVENTION OR TREATMENT OF HYPERLIPIDEMIA COMPRISING TRIGONAL GLUCAGON/GLP-1/GIP RECEPTOR AGONIST OR CONJUGATE THEREOF AND METHOD USING THE SAME

#117
20230142095
2023-05-11

Long-acting adrenomedullin derivative

#118
20230137773
2023-05-04

RAS INHIBITORY PEPTIDES AND USES THEREOF

#119
20230127047
2023-04-27

SELECTIVE GIP RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING AND THERAPY PURPOSES

#120
20230125604
2023-04-27

ANTI-PACAP ANTIBODIES AND USES THEREOF

#121
20230120030
2023-04-20

Long-Acting Adrenomedullin Derivatives

#122
20230115655
2023-04-13

ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION

#123
20230103631
2023-04-06

PEPTIDES AS SELECTIVE GIP RECEPTOR AGONISTS

#124
20230102339
2023-03-30

INCRETIN ANALOGS AND USES THEREOF

#125
20230059111
2023-02-23

Translatable molecules and synthesis thereof

#126
20230041692
2023-02-09

NOVEL PEPTIDE HORMONES

#127
20230036131
2023-02-02

Genetically modified probiotics for oral delivery of renin-angiotensin related therapeutic proteins and peptides

#128
20230013523
2023-01-19

Mucoadhesive microorganism

#129
20230000952
2023-01-05

THERAPEUTIC AGENTS COMPRISING ELASTIN-LIKE PEPTIDES

#130
20220411477
2022-12-29

ANTI-MULLERIAN HORMONE POLYPEPTIDES

#131
20220409774
2022-12-29

ERYTHROPOIETIN COMPOSITIONS AND METHODS OF USE

#132
20220402986
2022-12-22

PRODUCTION OF GLYCOPROTEINS USING MANGANESE

#133
20220389076
2022-12-08

MODIFIED IMMUNE CELL AND USE THEREOF

#134
20220372101
2022-11-24

NOVEL RECEPTORS HAVING A HETEROLOGOUS STOP TRANSFER SEQUENCE FOR LIGAND-DEPENDENT TRANSCRIPTIONAL REGULATION

#135
20220372099
2022-11-24

CONJUGATED HEPCIDIN MIMETICS

#136
20220354960
2022-11-10

IMMUNE CHECKPOINT BLOCKING BISPECIFIC MOLECULES

#137
20220348626
2022-11-03

Hepcidin analogues and uses thereof

#138
20220340634
2022-10-27

Pharmaceutical preparation comprising recombinant HCG

#139
20220340633
2022-10-27

SUPERAGONIST POLYPEPTIDE ANALOGS OF ADRENOMEDULLIN AND INTERMEDIN PEPTIDE HORMONES

#140
20220324935
2022-10-13

Peptide analogs

#141
20220289809
2022-09-15

USE OF RELAXIN TO TREAT ATRIAL FIBRILLATION

#142
20220288168
2022-09-15

Long acting amylin receptor agonists and uses thereof

#143
20220281938
2022-09-08

Biotechnology for curing hypothyroidism

#144
20220280658
2022-09-08

SATIATION PEPTIDES FOR WEIGHT LOSS AND ALTERED TASTE SENSITIVITY

#145
20220275038
2022-09-01

CLSP DERIVATIVE INCAPABLE OF BEING AFFECTED BY CLSP INHIBITING SUBSTANCE, AND CLSP ACTIVITY ENHANCING/PROTECTING AGENT

#146
20220267401
2022-08-25

METHOD FOR PRODUCING AND PURIFYING HYBRID OR NON-HYBRID RECOMBINANT GLYCOPROTEIN HORMONES, HYBRID OR NON-HYBRID RECOMBINANT GLYCOPROTEIN HORMONES, EXPRESSION VECTORS AND USES OF THE RECOMBINANT GLYCOPROTEIN HORMONES

#147
20220257719
2022-08-18

APPETITE SUPPRESSING COMPOUNDS

#148
20220211816
2022-07-07

IDENTIFICATION OF A NEW POLYPEPTIDE HORMONE FOR MAINTENANCE OF OPTIMAL BODY WEIGHT AND BLOOD GLUCOSE

#149
20220211806
2022-07-07

METHOD FOR PROMOTING BONE GROWTH USING ACTIVIN-ACTRIIA ANTAGONISTS

#150
20220204581
2022-06-30

MONOMERIC PEPTIDE MULTI-AGONIST TARGETING THE GLP1 RECEPTOR AND NPY RECEPTORS

#151
20220204580
2022-06-30

POLYPEPTIDES AND USES THEREOF

#152
20220204553
2022-06-30

METHODS FOR THE FRACTIONATION OF PROTEINS

#153
20220195022
2022-06-23

Polynucleotides encoding monoclonal antibodies binding to human pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1) and methods of making thereof

#154
20220177537
2022-06-09

Long-acting oxyntomodulin hybrid peptide, preparation method therefor, and application thereof

#155
20220169712
2022-06-02

METHOD FOR REDUCING THE IMMUNE RESPONSE TO A BIOLOGICALLY ACTIVE PROTEIN

#156
20220162281
2022-05-26

RECOMBINANT IRISIN GENE OPTIMIZED FOR EXPRESSION IN PLANTS AND METHOD FOR PRODUCING RECOMBINANT IRISIN PROTEIN USING SAME

#157
20220160816
2022-05-26

ANGIOTENSIN COMPOSITIONS AND METHODS RELATED THERETO

#158
20220143201
2022-05-12

COMPOSITION COMPRISING A POLYMERIC REAGENT

#159
20220135638
2022-05-05

GIP receptor agonist peptide compounds and uses thereof

#160
20220133898
2022-05-05

Derivatisation of Insulin with Polysaccharides

#161
20220119516
2022-04-21

VARIANTS OF ERYTHROFERRONE AND THEIR USE

#162
20220119473
2022-04-21

Acylated oxyntomodulin peptide analog

#163
20220112261
2022-04-14

PEPTIDE TARGETING GIP AND GLP-2 RECEPTORS FOR TREATING BONE DISORDERS

#164
20220106376
2022-04-07

METHODS, COMPOSITIONS AND USES THEREOF FOR REVERSING SACROPENIA

#165
20220106372
2022-04-07

Methods, compositions and uses thereof for reversing sarcopenia

#166
20220072104
2022-03-10

MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF

#167
20220056097
2022-02-24

SYSTEMS AND METHODS FOR COMPARTMENT SPATIAL ORGANIZATION

#168
20220041678
2022-02-10

SOLUBLE NPY2 RECEPTOR AGONISTS

#169
20220041677
2022-02-10

MODIFIED MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS AND USES THEREOF FOR THE TREATMENT OF DISEASES

#170
20220041676
2022-02-10

GIP agonist compounds and methods

#171
20220025008
2022-01-27

RECOMBINANT ANTIBODY OF ANTI-HUMAN N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE

#172
20220009987
2022-01-13

HUMAN RESISTIN COMPOSITIONS AND METHODS OF TREATING TLR4-MEDIATED DISEASE AND INFECTION

#173
20220002371
2022-01-06

Long acting peptide tyrosine tyrosine (PYY) analogs and methods of use

#174
20220002368
2022-01-06

DUAL FUNCTION PROTEINS COMPRISING FGF21 MUTANT PROTEIN AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

#175
20210403551
2021-12-30

Method of treatment with a fusion protein comprising apelin and an anti-APLNR antibody

#176
20210401942
2021-12-30

Satiation peptide administration

#177
20210371487
2021-12-02

METHODS OF PRODUCING LONG ACTING CTP-MODIFIED POLYPEPTIDES

#178
20210347882
2021-11-11

Method for treating pulmonary hypertension with antibodies to human Resistin

#179
20210346468
2021-11-11

Amylin analogues

#180
20210332335
2021-10-28

In vivo protein N-acylation

#181
20210301001
2021-09-30

ANTIBODY THAT BINDS MURINE WISE PROTEIN

#182
20210261641
2021-08-26

Compounds for treatment of obesity

#183
20210230244
2021-07-29

Peptide complex with immunodulatory and anti-inflammatory function

#184
20210230216
2021-07-29

Method for purifying long chain polypeptide

#185
20210214408
2021-07-15

TARGETING ANABOLIC DRUGS FOR ACCELERATED FRACTURE REPAIR

#186
20210212311
2021-07-15

STORAGE SOLUTION COMPOSITIONS FOR THE STABILIZATION OF PURIFIED MÜLLERIAN INHIBITING SUBSTANCE (MIS) AND METHODS OF USE AND PRODUCTION RELATED THERETO

#187
20210206822
2021-07-08

Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors

#188
20210179688
2021-06-17

Treatment of headache, migraine and/or photophobia conditions using humanized anti-PACAP antibodies

#189
20210172964
2021-06-10

Reference standard for BNP measurement

#190
20210171598
2021-06-10

PEPTIDE HORMONE WITH ONE OR MORE O-GLYCANS

#191
20210163566
2021-06-03

Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors

#192
20210147504
2021-05-20

BRAIN NATRIURETIC PEPTIDE ENGRAFTED ANTIBODIES

#193
20210147483
2021-05-20

Analogues of hepcidin mimetics with improved in vivo half lives

#194
20210128598
2021-05-06

Radiation-Sterilized Biodegradable Drug Delivery Compositions

#195
20210122799
2021-04-29

Self-assembling peptide for activating human mast cells

#196
20210115104
2021-04-22

AMYLIN ANALOGUES

#197
20210115103
2021-04-22

Long-acting adrenomedullin derivative conjugated with Fc region of immunoglobulin

#198
20210101952
2021-04-08

Engineered Optimized Cytokine Compositions

#199
20210094998
2021-04-01

Immunoglobulins and uses thereof

#200
20210085766
2021-03-25

AMH-INH-GNIH tri-expression gene vaccine of improving fecundity of animals, preparation method and application

#201
20210079438
2021-03-18

CARBOHYDRATE ESTERS AS INDUCERS FOR GENE EXPRESSION

#202
20210070815
2021-03-11

Mucoadhesive microorganism

#203
20210061893
2021-03-04

Diagnostic kit

#204
20210061872
2021-03-04

CONJUGATED HEPCIDIN MIMETICS

#205
20210054346
2021-02-25

SELECTION METHODS FOR GENETICALLY-MODIFIED T CELLS

#206
20210047398
2021-02-18

ASPROSIN, A FAST-INDUCED GLUCOGENIC PROTEIN HORMONE

#207
20210047381
2021-02-18

Production of Glycoproteins Using Manganese

#208
20210040192
2021-02-11

METHOD OF PROMOTING BONE GROWTH BY AN ANTI-ACTRIIA ANTIBODY

#209
20210032371
2021-02-04

Enhanced immunogenicity for GPI-anchored antigens

#210
20210017261
2021-01-21

Methods for treating a headache condition using anti-human PAC1 antibodies or antigen-binding fragments thereof

#211
20210015902
2021-01-21

ANGIOPOIETIN-LIKE PROTEIN 8 POLYPEPTIDE FRAGMENTS AND COMPOSITIONS THEREOF

#212
20210008219
2021-01-14

Long-acting adrenomedullin derivative

#213
20200385439
2020-12-10

Immunoglobulins and uses thereof

#214
20200362006
2020-11-19

Engineered polypeptides having enhanced duration of action

#215
20200354425
2020-11-12

Acylated oxyntomodulin peptide analog

#216
20200347110
2020-11-05

Composition and Methods for Stimulating Gastrointestinal Motility

#217
20200339649
2020-10-29

Peptide analogs

#218
20200333351
2020-10-22

Compounds and methods for conjugation of biomolecules

#219
20200300873
2020-09-24

KITS FOR DETECTION OF HEPCIDIN

#220
20200291102
2020-09-17

METHOD FOR REDUCING THE IMMUNE RESPONSE TO A BIOLOGICALLY ACTIVE PROTEIN

#221
20200291086
2020-09-17

BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS

#222
20200283491
2020-09-10

Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors

#223
20200283471
2020-09-10

LONG ACTING PROTEINS AND PEPTIDES AND METHODS OF MAKING AND USING THE SAME

#224
20200282022
2020-09-10

Therapeutic agents comprising a BMP-9 peptide and eleastin-like peptides

#225
20200276320
2020-09-03

Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates

#226
20200261490
2020-08-20

Pappalysin regulator

#227
20200247864
2020-08-06

Combinatorial gene construct and non-viral delivery for anti-obesity

#228
20200247863
2020-08-06

Pharmaceutical preparation comprising recombinant hCG

#229
20200239537
2020-07-30

Apelin peptides and uses thereof

#230
20200239536
2020-07-30

CYCLIC GALANIN-ANALOGS AND USES THEREOF

#231
20200239533
2020-07-30

Ras inhibitory peptides and uses thereof

#232
20200188485
2020-06-18

Amylin analogues

#233
20200181230
2020-06-11

Humanized anti-PACAP antibodies

#234
20200181229
2020-06-11

Humanized anti-PACAP antibodies

#235
20200165316
2020-05-28

Humanized anti-PACAP antibodies

#236
20200115430
2020-04-16

Human amylin analog polypeptides and methods of use

#237
20200088746
2020-03-19

QUANTIFICATION OF TRANSTHYRETIN AND ITS ISOFORMS

#238
20200087371
2020-03-19

USE OF RELAXIN TO TREAT ATRIAL FIBRILLATION

#239
20200071376
2020-03-05

Mullerian inhibiting substance (MIS) proteins for ovarian and uterine oncoprotection, and ovarian reserve and uterine preservation

#240
20200063111
2020-02-27

In vivo protein N-acylation

#241
20200061158
2020-02-27

Satiation peptide administration

#242
20200055913
2020-02-20

HUMAN RESISTIN COMPOSITIONS AND METHODS OF TREATING TLR4-MEDIATED DISEASE AND INFECTION

#243
20200040054
2020-02-06

ERFE FUSION POLYPEPTIDES COMPOSITIONS AND METHODS OF USE

#244
20200030413
2020-01-30

Methods and pharmaceutical compositions for the treatment of kidney cancer

#245
20200024320
2020-01-23

Variants of adrenomedullin and calcitonin gene-related peptide and methods of use

#246
20200024318
2020-01-23

Dual function proteins comprising FGF21 mutant protein and pharmaceutical composition comprising same

#247
20200017567
2020-01-16

NPRA AGONISTS, COMPOSITIONS, AND USES THEREOF

#248
20200017566
2020-01-16

HEPCIDIN AND MINI-HEPCIDIN ANALOGUES AND USES THEROF

#249
20200010523
2020-01-09

Chimera of bone morphogenic protein 2 and the Müllerian-inhibiting substance type II receptor binding region of Müllerian-inhibiting substance

#250
20200002397
2020-01-02

Protein and protein conjugate for diabetes treatment, and applications thereof

#251
20190390170
2019-12-26

METHODS FOR MODULATING PRODUCTION PROFILES OF RECOMBINANT PROTEINS

#252
20190382439
2019-12-19

METHOD FOR EXTENDING HALF-LIFE OF A PROTEIN

#253
20190369117
2019-12-05

Antibodies recognizing genetic variants of NT-proBNP

#254
20190367578
2019-12-05

GIP derivatives and uses thereof

#255
20190367577
2019-12-05

Immunoglobulins and uses thereof

#256
20190359674
2019-11-28

Proteolically resistant cyclotides with angiotensin 1-7 like activity

#257
20190351026
2019-11-21

USES OF MODIFIED MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

#258
20190345214
2019-11-14

Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors

#259
20190328887
2019-10-31

METABOLICALLY STABLE PEPTIDE ANALOGS

#260
20190321485
2019-10-24

Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof

#261
20190309277
2019-10-10

Fusion proteins comprising a non-cytotoxic protease, a translocation domain, and a targeting moiety that binds a galanin receptor and methods for treating, preventing or ameliorating pain using such fusion proteins

#262
20190298849
2019-10-03

Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors

#263
20190284551
2019-09-19

Conditionally Active Biological Proteins

#264
20190282665
2019-09-19

Compositions comprising relaxin and methods of use thereof

#265
20190282664
2019-09-19

METHODS FOR STIMULATION OF APPETITE AND INCREASE IN WEIGHT BY ADMINISTRATION OF ASPROSIN

#266
20190263879
2019-08-29

Immunoglobulins and uses thereof

#267
20190263878
2019-08-29

Genetically modified probiotics for oral delivery of renin-angiotensin related therapeutic proteins and peptides

#268
20190256569
2019-08-22

GIP agonist compounds and methods

#269
20190248861
2019-08-15

Composition and Methods for Stimulating Gastrointestinal Motility

#270
20190233498
2019-08-01

Anti-PACAP antibodies and uses thereof

#271
20190218279
2019-07-18

PAC1 antibodies and uses thereof

#272
20190218274
2019-07-18

ELP FUSION PROTEINS FOR CONTROLLED AND SUSTAINED RELEASE

#273
20190218259
2019-07-18

Compositions and methods for brown fat induction and activity using FNDC5

#274
20190216938
2019-07-18

Derivatisation of Insulin with Polysaccharides

#275
20190216901
2019-07-18

ACTH PROPHYLACTIC TREATMENT OF RENAL DISORDERS

#276
20190211062
2019-07-11

Modified proteins and methods of use thereof

#277
20190203248
2019-07-04

Serum albumin binding molecules

#278
20190202883
2019-07-04

Peptide compound

#279
20190195896
2019-06-27

Antibodies to TTR and methods of use

#280
20190194267
2019-06-27

Mucoadhesive microorganism

#281
20190194246
2019-06-27

SOLID PHASE PEPTIDE SYNTHESIS

#282
20190192625
2019-06-27

Method for promoting bone growth using activin-actriia antagonists

#283
20190185536
2019-06-20

Hepcidin analogues and uses thereof

#284
20190185535
2019-06-20

Hepcidin analogues and uses thereof

#285
20190185484
2019-06-20

Cortistatin analogues and syntheses and uses thereof

#286
20190183978
2019-06-20

Long-acting peptide analogs

#287
20190183962
2019-06-20

ANGIOTENSIN COMPOSITIONS AND METHODS RELATED THERETO

#288
20190177410
2019-06-13

Fusion protein comprising apelin and an anti-APLNR antibody

#289
20190177391
2019-06-13

ANGIOPOIETIN-LIKE PROTEIN 8 (ANGPTL8)

#290
20190177362
2019-06-13

Amino diacids containing peptide modifiers

#291
20190160160
2019-05-30

Methods to Treat Diseases with Protein, Peptide and Antigen Modification

#292
20190160151
2019-05-30

Method for preventing or treating heart failure by administering a medicament containing an antagonist of corticotropin releasing hormone receptor 2 (CRHR2)

#293
20190153059
2019-05-23

PEPTIDE ANALOGS

#294
20190135887
2019-05-09

METABOLICALLY STABLE SPEXIN PEPTIDE ANALOGS

#295
20190135886
2019-05-09

GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS

#296
20190135885
2019-05-09

COMPOSITION COMPRISING AN AB6 FAMILY DESIGNER LIGAND OF TGF-BETA SUPERFAMILY FOR TREATING LIVER DISEASE AND USE THEREOF

#297
20190134159
2019-05-09

AMYLIN ANALOGUES

#298
20190117737
2019-04-25

GLP-1R/GCGR dual target agonist polypeptide for treatment of fatty liver diseases, hyperlipemia and arteriosclerosis

#299
20190091297
2019-03-28

Methods of increasing nutrient absorption in the intestine using therapeutic agents comprising GLP-2 and elastin-like peptides

#300
20190085043
2019-03-21

FUSION PROTEINS FOR TREATING A METABOLIC SYNDROME